safety of dosages exceeding 480 mg/d in angina pectoris have not been established. Since the drug is largely metabolized by the liver and excreted by the kidneys, hepatic or renal disease may require dosage reduction.
References1. Brodsky SJ, Cutler SS, Werner DA, McCabe CH, Ryan TJ, Klein MD. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. Circulation 1982;66:569-74. 2. Pine MB, Citron PD, Bailly DJ, et al. Verapamil versus placebo in relieving stable angina pectoris. Circulation 1982;65: 17-22. 3. BalaSubramanian V, lahiri A, Paramasivan R, Raftery EB. Verapamil in chronic stable angina: a controlled study with computerized multistage treadmill exercise. Lancet 1980;/:841-4. 4. leon MB, Rosing DR, Bonow RO, lipsen lC, Epstein SE. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardio/1981;48:131-9. 5. Bowles MJ, BalaSubramanian V, Davies AB, Raftery EB. Comparison of antianginal actions of verapamil and propranolol. Br Med J 1981;282:1754. 6. Frishman WH, Klein NA, Strom JA, et al. Superiority of veraparnil to propranolol in stable angina pectoris: a double-blind randomized crossover trial. Circulation 1982;65(suppl 1):51-9. 7. Parodi 0, Maseri A, Simonetti I. Management of unstable angina at rest by verapamil: a double-blind crossover study in coronary care unit. Br Heart J 1979;4/:167-74. 8. Parodi 0, Simonetti I, Lazzari M, et al. Propranolol versus verapamil in unstable angina: results in a single-blind double crossover trial in CCU. Am J Cardio/1982;49:930.